Literature DB >> 21414566

β2 adrenergic receptor polymorphisms and nocturnal blood pressure dipping status in the Wisconsin Sleep Cohort Study.

Orly Vardeny1, Paul E Peppard, Laurel A Finn, Juliette H Faraco, Emmanuel Mignot, Khin Mae Hla.   

Abstract

Nondipping nocturnal blood pressure (BP) is associated with target organ damage and cardiovascular disease. We hypothesized that β1- and β2-AR-associated single nucleotide polymorphisms (SNPs) would associate with nondipping BP patterns. Participants (n = 497, age range 30-74 years, 40% female) of the Wisconsin Sleep Cohort Study with at least one ambulatory BP monitoring test were included. Nondipping was defined as less than a 10% dip in sleep BP compared with wake BP. Dipping ratios were calculated as sleep/wake BP. Single nucleotide polymorphisms in the β1-AR (rs7076938, tagging for Gly389Arg) and β2-AR (rs17778257 and rs2400707, tagging for Arg16Gly and Gln27Glu) were selected. β2-AR SNP rs2400707 A-positive subjects (tagging for Glu27) had higher systolic and diastolic dipping ratios in a dose-response fashion. Systolic dipping ratios were: GG = 0.846; AG = 0.854; AA = 0.861 (P = .015). Diastolic dip ratios were: GG = 0.807; AG = 0.815; AA = 0.824 (P = .026). The β2-AR rs17778257/rs2400707 A/A haplotype was associated with dipping ratios and systolic nondipping status (nondipping odds radio 2.0 [1.0-3.8] for A/A versus A/G). Results were similar when models included participants on antihypertensive medications. Higher dipping ratios indicating a lack of nocturnal BP dipping are associated with β2-AR polymorphisms. Nocturnal dipping patterns may be modulated by β2-AR polymorphisms.
Copyright © 2011 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21414566      PMCID: PMC3071556          DOI: 10.1016/j.jash.2011.01.005

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  40 in total

Review 1.  What are the influences of salt, potassium, the sympathetic nervous system, and the renin-angiotensin system on the circadian variation in blood pressure?

Authors:  D A Sica
Journal:  Blood Press Monit       Date:  1999       Impact factor: 1.444

2.  Polymorphism in the beta(1)-adrenergic receptor gene and hypertension.

Authors:  K Bengtsson; O Melander; M Orho-Melander; U Lindblad; J Ranstam; L Råstam; L Groop
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

3.  Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives.

Authors:  K Kario; T G Pickering; T Matsuo; S Hoshide; J E Schwartz; K Shimada
Journal:  Hypertension       Date:  2001-10       Impact factor: 10.190

4.  Association analysis of beta(2)-adrenergic receptor polymorphisms with hypertension in Japanese.

Authors:  N Kato; T Sugiyama; H Morita; H Kurihara; T Sato; Y Yamori; Y Yazaki
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

5.  Polymorphisms of the beta2 -adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies.

Authors:  Stefan-Martin Herrmann; Viviane Nicaud; Laurence Tiret; Alun Evans; Frank Kee; Jean-Bernard Ruidavets; Dominique Arveiler; Gerald Luc; Caroline Morrison; Margret R Hoehe; Martin Paul; François Cambien
Journal:  J Hypertens       Date:  2002-02       Impact factor: 4.844

6.  Nighttime blood pressure dipping: the role of the sympathetic nervous system.

Authors:  Andrew Sherwood; Patrick R Steffen; James A Blumenthal; Cynthia Kuhn; Alan L Hinderliter
Journal:  Am J Hypertens       Date:  2002-02       Impact factor: 2.689

7.  Positional genomic analysis identifies the beta(2)-adrenergic receptor gene as a susceptibility locus for human hypertension.

Authors:  M S Bray; J Krushkal; L Li; R Ferrell; S Kardia; C F Sing; S T Turner; E Boerwinkle
Journal:  Circulation       Date:  2000-06-27       Impact factor: 29.690

8.  The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization.

Authors:  V Dishy; G G Sofowora; H G Xie; R B Kim; D W Byrne; C M Stein; A J Wood
Journal:  N Engl J Med       Date:  2001-10-04       Impact factor: 91.245

9.  Adrenergic signaling polymorphisms and their impact on cardiovascular disease.

Authors:  Gerald W Dorn
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

10.  Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes.

Authors:  Empar Lurbe; Josep Redon; Ajit Kesani; Jose Maria Pascual; Jose Tacons; Vicente Alvarez; Daniel Batlle
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

View more
  6 in total

1.  β-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis.

Authors:  De-Run Kong; Jin-Guang Wang; Bin Sun; Ming-Quan Wang; Chen Chen; Fang-Fang Yu; Jian-Ming Xu
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

Review 2.  Cardiovascular health, traffic-related air pollution and noise: are associations mutually confounded? A systematic review.

Authors:  Louis-François Tétreault; Stéphane Perron; Audrey Smargiassi
Journal:  Int J Public Health       Date:  2013-07-26       Impact factor: 3.380

Review 3.  The potential contribution of stress systems to the transition to chronic whiplash-associated disorders.

Authors:  Samuel A McLean
Journal:  Spine (Phila Pa 1976)       Date:  2011-12-01       Impact factor: 3.468

Review 4.  Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms.

Authors:  Worapaka Manosroi; Gordon H Williams
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

5.  Association between single nucleotide polymorphisms in ADRB2, GNB3 and GSTP1 genes and high-altitude pulmonary edema (HAPE) in the Chinese Han population.

Authors:  Yongjun He; Lijun Liu; Pengcheng Xu; Na He; Dongya Yuan; Longli Kang; Tianbo Jin
Journal:  Oncotarget       Date:  2017-03-14

Review 6.  Ischemic Stroke and Sleep: The Linking Genetic Factors.

Authors:  Lyudmila Korostovtseva
Journal:  Cardiol Ther       Date:  2021-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.